Skip to content
CompanySight
Company No. 02753142 · Incorporated 5 Oct 1992

Altimmune UK Limited

Registered name: ALTIMMUNE UK LIMITED

Part of Altimmune, Inc. group

Altimmune UK Limited made £0 revenue and a £4m loss in the year to 31 Dec 2024.

Altimmune UK Limited’s revenue was £0 in the year to 31 Dec 2024, with a loss of £4m and 2 employees. The company is classified under “research and experimental development on biotechnology” and is based in Leeds; we hold 3 years of its filed accounts.

Full P&L filedSection M · Professional, scientific and technical activitiesSIC 72110Research and experimental development on biotechnology
Status
Active
Location
Leeds, Yorkshire and The Humber
Age
34 yrs · since 1992
Type
Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.

Latest accounts · year to 31 Dec 2024

Key figures

Small team
Revenue
£0
Growth —
Profit
−£4m
Growth —
Profit margin
—
 
Employees
2
Change 0%
Profit / employee
−£2m
Revenue/employee £0
Profitable streak
0yrs
Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

3 filed years

Financial history

Multi-year financials, oldest to newest
Year to31 Dec 202231 Dec 202331 Dec 2024
DisclosureFull P&LFull P&LFull P&L
Profit & loss
Revenue (turnover)£0£0£0
Cost of sales£8.5m£8.2m£3.9m
Gross profit−£8.5m−£8.2m−£3.9m
Operating profit−£9.3m−£8m−£4.4m
Profit before tax−£9.3m−£8m−£4.4m
Profit after tax−£8m−£6.9m−£4m
Profit (best available)−£8m−£6.9m−£4m
Employees (average)222
Ratios
Profit margin———
Revenue per employee£0£0£0
Profit per employee−£4m−£3.4m−£2m
Growth (year on year)
Headcount growth—0%0%
Balance sheet — indirect signals, not revenue
Cash at bank£1.6m£117k£76.1k
Net assets−£4.8m−£9.2m−£10.6m
Fixed assets£0£0£0
Current assets£3.7m£3.3m£1.6m
Debtors£2.1m£0£0
Deferred income—£0£0
SourceFullAccounts · bulk data Oct 2024FullAccounts · bulk data Oct 2024FullAccounts · bulk data Sep 2025
Derived from the latest filing

How the business works

Profit margin
—
Profit ÷ revenue.
Gross margin
—
Gross profit ÷ revenue. High for software and services.
Revenue per employee
£0
Revenue ÷ average employees.
Profit per employee
−£2m
Profit ÷ average employees.
Cash conversion
—
Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue
—
Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue
—
Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue
—
Money owed by customers. Low = customers pay quickly.
Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets
—
Now −£10.6m
Cash at bank
▼35%
Now £76.1k
Headcount
0%
Now 2
Deferred income
—
Now £0
Fixed assets
—
Now £0

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

  1. Altimmune, Inc. (registered outside the UK register)ultimate parent75–100%
  2. Altimmune UK Limitedthis company

Bands show the share of ownership each company holds in the one below it.

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Latest figures from FullAccounts for the year to 31 Dec 2024 (profit −£4m), from the Companies House accounts bulk data published Sep 2025. Spotted an error? Request a correction.

Updated from Companies House on 15 Oct 2026

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.